• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Enliven Therapeutics to Present at Upcoming Investor Conferences

    5/22/25 4:05:00 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELVN alert in real time by email

    BOULDER, Colo., May 22, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will present at the following investor conferences:

    TD Cowen's 6th Annual Oncology Innovation Summit: Insights from ASCO & EHA

    Format: Fireside Chat

    Date: Tuesday, May 27, 2025

    Time: 1:00 p.m. ET

    Jefferies Global Healthcare Conference

    Format: Fireside Chat

    Date: Wednesday, June 4, 2025

    Time: 4:20 p.m. ET

    Goldman Sachs Annual Global Healthcare Conference

    Format: Fireside Chat

    Date: Tuesday, June 10, 2025

    Time: 4:00 p.m. ET

    The fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. Each webcast will be archived for a period of 90 days following the conclusion of the live event.

    About Enliven Therapeutics

    Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.

    Enliven Logo (PRNewsfoto/Enliven Therapeutics, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-to-present-at-upcoming-investor-conferences-302463238.html

    SOURCE Enliven Therapeutics, Inc.

    Get the next $ELVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELVN

    DatePrice TargetRatingAnalyst
    6/16/2025$37.00Buy
    Goldman
    12/13/2024$42.00Buy
    BTIG Research
    9/9/2024$37.00Buy
    H.C. Wainwright
    6/11/2024$32.00Outperform
    Robert W. Baird
    4/9/2024$34.00Buy
    Mizuho
    3/29/2023$27.00Buy
    Jefferies
    3/3/2023Outperform
    TD Cowen
    More analyst ratings